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A B S T R A C T   
The burden of hypertension in Sub-Saharan African countries is rising. Low-cost and effective interventions are 
needed to mitigate these alarming trends. No evidence is available on the use of dietary nitrate for treating 
hypertension in African populations. The objectives of this study are to assess the feasibility and efficacy of using 
beetroot and folate as a combined dietary intervention to treat Tanzanian adults with pre- and mild to moderate 
hypertension. This was a three-arm double-blind, placebo-controlled, parallel randomised clinical trial con-
ducted within the Hai Demographic Surveillance Site in the Kilimanjaro region in Tanzania. 48 participants were 
randomised to one of three groups for a 60-day intervention period. Group 1: Combined dietary intervention 
(beetroot juice and folate), Group 2: Single dietary intervention (beetroot juice and placebo capsule), and Group 
3: Control group (placebo beetroot juice and placebo capsule). The primary outcome of the trial was to evaluate 
the feasibility of the study in a low-income setting. Trial assessments included resting clinic and ambulatory 24- 
hr blood pressure measurements, lifestyle and dietary questionnaires and collection of biological samples. Our 
cohort included 8 (16.7%) males and 40 (83.3%) females with mean age 60.7 years (SD 6.5). The mean (SD) BMI, 
clinic systolic blood pressure and ambulatory systolic blood pressure at baseline were 27.6 kg/m2 (5.4), 151.0 
(19.4), and 140.4 (15.0) mmHg, respectively. Eight (16.7%) participants were classified as pre-hypertensive, 20 
(41.7%) as stage-1 hypertensive, and 20 (41.7%) as stage-2 hypertensive. Overall, the results support the 
feasibility of a study of this nature within a hypertensive African population. 
Trial registration number: ISRCTN67978523.   
1. Introduction 
Hypertension is associated with a significant risk of cardiovascular 
morbidity and mortality worldwide [1]. The United Republic of 
Tanzania is a developing country within the East African region of 
Sub-Saharan Africa. Research indicates that current Tanzanian man-
agement strategies are struggling to control the burgeoning hyperten-
sion epidemic [2]. A recent study conducted by our group established a 
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‘rule of sixths’ in a cohort of hypertensive patients, where 2/6th of the 
cohort were previously diagnosed, 1/6th of those with a diagnosis were 
on treatment, and only 1/6th of those on treatment were adequately 
controlled [3]. 
Optimal control of hypertension remains challenging and the rising 
prevalence of hypertension in Tanzania calls for effective interventions. 
The need to develop a low-cost intervention that is both acceptable to 
local communities and effective either alone or alongside current 
medication is urgently warranted. Dietary interventions may be a 
valuable potential solution. The Dietary Approach to Stop Hypertension 
(DASH) diet is one of the best proven non-pharmacologic interventions 
for the prevention of hypertension [4] and the high inorganic nitrate 
content in the DASH diet may be responsible for this effect [5]. Recent 
studies have shown that dietary nitrate supplementation can reduce 
blood pressure and improve endothelial dysfunction [6–8]. Proposed 
mechanisms involve the generation of nitrite and subsequently nitric 
oxide, which promotes vasodilation to lower blood pressure [9]. 
Beetroot is a vegetable that is easily grown and naturally rich in 
dietary nitrate [10]. Studies utilising beetroot juice as a nitrate supple-
ment have shown promising effects on reducing blood pressure [11]. 
One trial in healthy participants showed a reduced systolic and diastolic 
pressure of 10.4  mmHg and 8.0 mmHg respectively following a single 
dose after 3 h [9]. Similar benefits were seen in a sample of 
African-American women [12]. Additionally, folic acid is associated 
with mechanisms controlling the regulation of vascular tone (i.e., Nitric 
Oxide Synthase coupling, reduction of homocysteine) and its supple-
mentation has been associated with improvements in endothelial func-
tion and blood pressure [13–15]. 
Poor adherence to medical treatment and lack of health in-
frastructures are key factors contributing to the poor control of hyper-
tension in Tanzania [16–19]. Dietary supplementation could potentially 
address these issues. Firstly, individuals may be more willing to take 
dietary supplements over anti-hypertensives due to the reduced 
side-effect profile and cultural perceptions of Western medicine, which 
could improve adherence to treatment. Secondly, using dietary supple-
ments as an additional source of anti-hypertensive therapy may help 
alleviate the burden on already resource-limited healthcare systems, 
where a consistent supply of medication can often be unfeasible and 
expensive compared to obtaining dietary nitrate from foods that can be 
grown locally and sustainably. As beetroot and folate induce beneficial 
effects on BP via different mechanisms, a combined intervention may 
yield greater benefits compared to the consumption of each individually. 
To our knowledge, a combined dietary intervention focussed on folic 
acid and inorganic nitrate has not been conducted, especially in an Af-
rican setting. Therefore, the aim of our study was to determine the 
feasibility of using beetroot and folate to lower blood pressure, and its 
efficacy for use in this setting. 
2. Methods 
2.1. Study design 
Our study was a three-arm, placebo-controlled, double blind, rand-
omised clinical trial (RCT) that was conducted in the Hai Demographic 
Surveillance Site (DSS) in the Kilimanjaro region of Northern Tanzania. 
Participants were assessed at Hai District Hospital and Kware village 
dispensary and samples were processed and stored at the Kilimanjaro 
Clinical Research Institute (KCRI). Recruitment started in March 2018, 
with trial assessments beginning in May and finishing in August. 
In order to measure the effects of dietary intervention, we utilised 
clinic and ambulatory blood pressure measurements to examine changes 
in systolic and diastolic blood pressure. Blood and saliva samples were 
collected to evaluate compliance to the interventions (folic acid and 
nitrate) and measure biomarkers of nitric oxide production. The study 
comprised of four phases: (1) Recruitment, (2) Screening, (3) Random-
isation and Baseline, and (4) Intervention. Eligible participants were 
randomised into one of three groups for an intervention period of 60 
days:  
 Group 1–Combined Intervention Group (High-Nitrate Beetroot and 
Folic Acid)  
 Group 2–Single Intervention Group (High-Nitrate Beetroot and 
Placebo)  
 Group 3–Control Group (Nitrate-Depleted Beetroot and Placebo) 
The feasibility and acceptability of the intervention was evaluated 
through one-to-one qualitative interviews and participant compliance to 
the interventions and measurement protocols. 
2.2. Study objectives 
The primary objective of the study was to establish the feasibility, 
acceptability of intervention by participants and retention rate of the 
study. Secondary objectives included changes in 24-hr ambulatory blood 
pressure, whole-body nitric oxide production, homocysteine, C Reactive 
Protein, folate and plasma nitrate and salivary nitrate and nitrite 
concentrations. 
2.3. Sample size 
A formal statistical calculation of the sample size was not possible 
due to the lack of data on the effects of dietary nitrate on cardio- 
metabolic outcomes in sub-Saharan African populations. Therefore, 
we calculated our sample size using the approach for pilot trials pro-
posed by Whitehead et al. [20]. In addition, we also used data from a 
published trial testing the effects of dietary nitrate on blood pressure in 
hypertensive British patients to further support the appropriateness of 
the sample size calculation [21]. The trial reported a significant effect of 
inorganic nitrate supplementation on systolic 24hr ABPM after 6 weeks 
of supplementation in 68 drug naïve hypertensive patients. The differ-
ence in systolic BP between the nitrate and placebo group was 
  7.7  mmHg (95%CI 4.1–11.2) with an effect size of 0.39. Applying a 
two-sided ANOVA model for repeated measures, we estimated that 14 
participants per group (total sample size: 42) would be sufficient to 
detect a significant difference between placebo and nitrate intervention 
group with an alpha level of 0.05 and 80% power. A sample size of 15 
participants per arm would allow the detection of a medium effect size 
(δ  0.30–0.70) with 80% power and an alpha level less than 0.05. 
Therefore our study aimed to recruit 48 patients (16 per group) to allow 
for 10% drop out rate during the study. 
2.4. Eligibility criteria 
Participants were eligible if they were aged between 50 and 70 years, 
non-smokers and had an average systolic blood pressure between 130 
and 170  mmHg and a BMI ranging from 18.0 to 40.0 kg/m2. Exclusion 
criteria were determined by factors likely to affect the study outcomes 
due to their influence on cardio-metabolic function, vascular function, 
and participant compliance. A list of all the inclusion and exclusion 
criteria can be seen in Appendix 1. 
2.5. Recruitment 
Census enumerators, individuals with a formal role and experience in 
conducting census and research work in their village of residence, were 
trained in accordance with the study protocol and identified local par-
ticipants by convenience sampling. They obtained basic contact details, 
and a resting blood pressure measurement and invited willing partici-
pants to a full screening assessment at either of the two research sites: 
the Hai District Hospital or Kware village dispensary. 
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2.6. Screening 
Two assessments were conducted during the screening phase (A and 
B). At screening A, eligibility was assessed according to the study 
eligibility criteria (see above). This assessment included anthropometric 
measurements, clinic blood pressure measurements (CBPMs), electro-
cardiography, and a brief medical history concerning drugs, diet and 
smoking. If eligible and willing to participate in the study, participants 
were invited to screening B where pre-baseline and feasibility data 
regarding lifestyle habits, knowledge of hypertension, and attitudes to 
the intervention were evaluated. 
2.7. Randomisation and Baseline 
Forty-eight eligible hypertensive individuals were recruited and 
consented to participate and randomised as they were enrolled in the 
trial. Participants were anonymised using three letter codes. Block- 
randomisation (4 participants per block) was used to generate a 
random sequence of codes for each intervention (Group 1, 2 or 3) and 
participants were assigned into one of the three arms of the trial ac-
cording to their group number. Participants and the research team were 
blinded to the intervention. The head of the laboratory at Kilimanjaro 
Clinical Research Institute (KCRI) was responsible for the list of un-
blinded participants and dispensing of the interventions to ensure 
blinding of the trial was maintained. After randomisation, baseline visits 
were conducted and the interventions were dispensed. 
2.8. Intervention 
Following randomisation and baseline measures, 16 participants 
were assigned to each one of the three intervention groups for a period 
of 60 days. Measurements were taken at the research sites at baseline 
(day 0), interim (day 30), and at the end of the study (day 60). A tele-
phone interview was conducted around 15 days after commencing the 
intervention to assess participant adherence and any concerns. Partici-
pants were asked to maintain their usual dietary habits, physical activity 
level and alcohol and caffeinated drinks consumption during the trial. 
All capsules were stored in identical white containers showing the in-
dividual participant code, the number of capsules, expiry date, storage 
and prescription instructions. Subjects were provided with a form to 
record the time of consumption and any problems they had with the 
interventions. 
Group 1 – “Combined Intervention: Nitrate-rich beetroot juice and folate 
capsule”. 
Participants were given one bottle (70 ml) of concentrated beetroot 
juice (Beet It shots®, James White LTD, UK) and one capsule of folate to 
be taken every morning. The juice corresponded to an average supple-
mentation of approximately 400 mg of inorganic nitrate per day, and 
each capsule contained 5 mg of folate (Folic Acid, 5 mg, Bio-Tech 
Pharmacal. Inc, USA). 
Group 2 – “Single Intervention: Nitrate rich beetroot juice and placebo 
capsule”. 
Participants were given the same bottle (70 ml) of concentrated 
beetroot juice as group 1 (Beet It shots®, James White LTD, UK), and one 
placebo capsule containing sucrose powder to be taken every morning. 
Group 3 – “Control Group: Placebo juice and placebo capsule”. 
Participants were given one bottle (70 ml) of nitrate-depleted beet-
root juice (<1 mg of inorganic nitrate, James White LTD, UK) and a 
placebo capsule containing sucrose powder to be taken every morning. 
This juice corresponded to an average supplementation of <1 mg of 
nitrate, and had the same appearance, colour and taste as the nitrate rich 
beetroot juice. The placebo capsules had the colour and appearance of 
the folic acid capsules. 
2.9. Study measures 
See Table 1 for a summary of the data collected at each visit. 
2.9.1. Anthropometric measurements 
Height, weight, mid-upper arm circumference (MUAC) and waist 
circumference were measured. Height was measured using a wall tape 
measure and weight was measured using calibrated weighing scales. 
Participants were fully clothed and barefoot for these measurements. 
BMI was calculated using these data. Mid-upper arm circumference was 
measured at the mid-point of the olecranon and acromion and waist 
circumference was measured at the level of the umbilicus. 
2.9.2. Clinic Blood Pressure Measurement (CBPM) 
Resting CBPMs were carried out in accordance with the World 
Health Organisation STEPS protocol [22] using a calibrated automatic 
OMRON M3 BP device. Participants were asked to rest in a sitting po-
sition for at least 15 min. BP was measured using an appropriate sized 
cuff (regular or large) on the left upper arm supported at the level of the 
heart. BP was taken three times with a 1-min break in between each 
measurement. The average of the second and third values was recorded 
and used in the study. 
2.9.3. Ambulatory 24-h blood pressure monitoring (ABPM) 
Participants were fitted with a 24-h ABPMs (Mobil-O-Graph [23], 
Stolberg, Germany) consisting of an inflatable cuff attached to small 
monitoring device. This device met the European Society of Hyperten-
sion and Association for Advancement of Medical Instrument criteria for 
BP measurements [24,25]. The cuff was secured around the individual’s 
left upper arm according to mid-upper arm circumference (small, 
20–24 cm; medium, 24–32 cm; large, 32–38 cm). A practice reading was 
taken in order to activate the monitor. Readings were then taken every 
30 min in the day from 08:00 to 20:00 and every hour overnight from 
20:00 to 08:00 the subsequent day. The following day, the participant 
would return the monitor and the BP data were uploaded onto the 
computer software. 
2.9.4. International physical activity questionnaire (IPAQ) 
The short English IPAQ [26] was used to assess daily activity levels of 
participants. 
2.9.5. Oral nitrate test (ONT) 
Eight saliva samples were taken to measure whole-body NO pro-
duction [27]. As part of the ONT, participants were given water bottles 
with a known nitrate concentration, and a low nitrate meal to eat be-
tween 13:00–13:30. Participants were then instructed to drink an oral 
labelled sodium nitrate dose of 4 mg of Na15NO3 (Sigma-Aldrich, UK) in 
100 mL of distilled water that was provided. Two hours after this, par-
ticipants could eat another low nitrate snack before collecting their 
saliva samples. The first samples were collected at the research sites 
under supervision, after which the participants were given the equip-
ment to collect samples at home and return them the next day. In order 
to take the samples, participants were instructed to chew on a cotton ball 
and then place the ball into a syringe to extract the saliva into tubes. 
Samples were collected into 2 mL Eppendorf tube containing 3.7 μL of 
sodium hydroxide to prevent degradation of nitrate during the collec-
tion procedure. Samples were stored at   20 C at KCRI before shipment 
to the UK once the trial was completed. Saliva samples were derivatized 
using the nitromesitylene method and the enrichment level of the tracer 
was determined using gas chromatography/mass spectrometry [28]. 
2.9.6. Salivary strips 
Berkeley® NO salivary strips [29] were used to measure salivary 
nitrite at the study visits to evaluate their validity as a measure of 
compliance to nitrate interventions. A strip was placed on the tongue 
which changes colour upon saliva exposure. The participant’s salivary 
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nitrite levels were graded against a colour wheel supplied by the 
manufacturer [Appendix 2]. 
2.9.7. Blood samples 
At screening A, all participants had their full blood count measured 
for haemoglobin level to screen for anaemia. For eligible participants, 
blood samples were collected in 9 ml lithium heparin tubes at each study 
visit. After collection, all lithium heparin blood samples were immedi-
ately labelled and kept in ice boxes before being transferred to KCRI, 
where they were centrifuged into three plasma aliquots and stored at 
  80 C until shipment to the UK. These were analysed for nitrate, folate, 
C Reactive Protein, nitro-tyrosine and homocysteine levels. 
2.9.8. Feasibility questionnaire 
At screening visit B, semi-structured interviews were conducted in 
Swahili and English. The survey was split into three major domains: (1) 
Hypertension knowledge and perceptions of own health, (2) Attitudes to 
medication & dietary intervention and (3) Acceptability of the study 
protocol. Open and closed questions were utilised throughout. The data 
collected from open questions were later analysed for reoccurring 
themes and categorised. Closed questions gave simple categorical and 
numeric data, and a Likert scale was used in some instances. Exploratory 
probes were used to ensure participants had answered fully. Clarifying 
probes were used to address any ambiguities created as a result of 
mistranslation from Swahili into English. The survey also collected de-
mographic information, family history and details of diet. The feedback 
questionnaires used in the study are showed in the online supplementary 
material. 
2.9.9. Telephone call (Day 15) 
Approximately 15 days into the intervention, participants were 
called to assess their compliance and report difficulties with the inter-
vention using a standardised questionnaire. 
2.9.10. Feedback questionnaires 
A short feedback questionnaire at the interim visit (day 30), and a 
longer questionnaire at the end of the study (day 60) were completed to 
evaluate the feasibility and acceptability of the intervention. 
All questionnaires used in the study are showed in the supplementary 
material. 
2.10. Ethics 
Ethical approval was obtained from Newcastle University, Kili-
manjaro Christian Medical Centre (KCMC) research ethics committee 
(REC) and the National Institute of Medical Research Ethics Committees 
in Tanzania. Verbal consent was obtained in the villages by the enu-
merators during the recruitment phase. After screening A, all partici-
pants were given their test results and had the results explained to them. 
At screening B visits, information packs were given and informed con-
sent was obtained from eligible participants before enrolment into the 
study. For individuals who were unable to write their own signature, 
thumbprints were taken to acknowledge their consent to participate. 
Participants were informed that they had the right to refuse consent and 
withdraw from the study at any time without having to give a reason. 
Those who were excluded were given appropriate medical advice and 
then referred to local health services for follow up. Participants were 
reimbursed for their travel costs when attending the research sites. 
2.11. Trial registration and SPIRIT guidelines 
The trial has been registered on the ISRCTN registry (Trial Number: 
ISRCTN67978523). The manuscript has been written in adherence with 
the SPIRIT Guidelines for describing protocol of clinical trials [30]. 
2.12. Statistical analysis 
Continuous variables were described as mean  SD. Categorical 
variables were summarised using absolute number and percentage of 
cases. Chi-square test was used to evaluate differences between groups 
for categorical variables. One-way analysis of variance was used to 
evaluate differences between groups for continuous variables. A p value 
less than 0.05 was considered as statistically significant. Statistical an-
alyses were carried out using SPSS software (Version 24, NY, USA). 
3. Results 
3.1. Recruitment flowchart 
In total, 94 participants were screened over an 8-week period be-
tween March and April 2018, with baseline visits starting in May 2018. 
Forty-eight participants met the inclusion criteria and were successfully 
randomised to one of the three interventions. Four individuals were 
Table 1 
Summary of the data and biological samples collected throughout the study. ABPM Ambulatory Blood Pressure Measurement, CBPM  Clinic Blood Pressure 
Measurement, ECG  Electrocardiography, FBC  Full Blood Count, ONT  Oral Nitrate Test, IPAQ  International Physical Activity Questionnaire, LH  Lithium 
Heparin.  
Data Collected Time Point 
Enumerator 
Visits 
Screening 
A 
Screening 
B 
Baseline 
(Day 0) 
Telephone Call Interim 
(Day 30) 
Final Visit 
(Day 60) 
Socio-demographic details 
(Name, age, gender) 
Y Y   Participants were called at around 15 days to see if 
they were experiencing any difficulties with the 
intervention   Contact Details (Phone, 
Address) 
Y y     
Resting Blood Pressure Y      
Eligibility (FBC, ECG, 
Medical History)  
Y     
Informed Consent   Y    
IPAQ   Y   Y 
Anthropometry  Y  Y Y Y 
CBPM  Y  Y Y Y 
ABPM    Y  Y 
LH Blood sample    Y Y Y 
ONT    Y  Y 
Salivary Strips    Y Y Y 
Feasibility Questionnaires   Y    
Feedback Questionnaires 
(FQ)     
Short FQ Full FQ  
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unable to complete the pre-baseline assessments at screening B. One 
participant was lost to follow up as they moved to a new city and so 
interventions were dispensed to 47 participants at baseline (Fig. 1). 
3.2. Demographics 
Baseline characteristics of the cohort are shown in Table 2. There 
were 8 (16.7%) males and 40 (83.3%) females with a mean age of 61.8 
and 60.6 respectively. Forty (83.3%) belonged to the Chagga tribe and 
28 (58.3%) members of the cohort had an occupation that involved 
farming. Active smokers were excluded. Apart from gender, groups were 
generally well matched across variables. 
3.3. Baseline data 
Hypertensive grading according to clinical guidelines can be found in 
Table 3. Table 4 shows the anthropometric and blood pressure charac-
teristics of the cohort who started the intervention. 
Forty-four participants completed the IPAQ. Most of the cohort had 
high MET (Metabolic Equivalents) scores, owing to high levels of weekly 
physical activity (Table 5). Twenty-four reported to not perform 
vigorous activity, resulting in a low LQ and median for vigorous activity 
scores. Thirty-nine (86.6%) were classified as having high levels of ac-
tivity, with most time spent doing moderate activity such as farming or 
cultivating. Mean haemoglobin levels of the cohort were 14.1  1.2  g/ 
dL (range: 11.7–17.2  g/dL). Salivary strips were taken from 46 partic-
ipants at baseline. No participants had a salivary nitrite grade of target 
or higher (Fig. 2). 
4. Discussion 
In this study, we have demonstrated the rationale, design and 
baseline data of the participants who took part in our dietary inter-
vention trial. Important findings regarding our methodology and base-
line data are discussed below. 
Firstly, enumerators were an invaluable resource during the 
recruitment phase of our trial and provided valuable insight into cultural 
beliefs within the area. This helped adapt our study protocol to be more 
acceptable to the community. As an example, the initial role of the 
enumerators was to identify individuals who were likely to meet the 
study criteria and selectively invite them to screening in order to 
streamline the recruitment process. In practice however, this was not 
culturally acceptable. Individuals that the enumerators deemed unlikely 
to meet the study criteria would complain that it was unfair that other 
people were being selected over them when they were also suffering 
from various illnesses. Consequently, we decided to screen anyone seen 
by the enumerators even if they were already unsuitable for the study. 
Whilst this increased the overall time required for the screening phase, 
many individuals expressed their gratitude for our presence, and this 
could have actually helped bring more participants to the research sites. 
Indeed, nine individuals came to the Kware dispensary for screening 
after hearing about the study from others. 
Our cohort was somewhat representative of the demographics of the 
Kilimanjaro region, in that most belonged to the Chagga tribe (83.3%) 
Fig. 1. Flowchart of the study up to the baseline visit.  
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and were farmers (58.3%) [3,31]. However, females were over-
represented. Enumerators often reported that men were away working 
on farms whilst they were conducting visits. As a result, more women 
were seen at home and available for the study. Other studies have also 
reported that women tend to have better health seeking behaviours than 
men which may have contributed to this disparity [16]. To limit the 
effect this may have on results, this issue should be addressed in future 
studies. Monetary incentives could be utilised to act as a substitute for 
lost pay and conducting the study in the dry season would help, as many 
participants reported being more likely to be available as they would not 
be doing farm work then. Moreover, heavy rains during our study often 
limited road accessibility, and our research team noted that participants 
were significantly late when coming to clinic on rainy days. The dry 
season in the Kilimanjaro region is June-December [32,33]. Overall, the 
total number of individuals approached by enumerators or self-referred 
to the study was 107. Therefore, the ratio for participants approached to 
included was roughly 2:1. This ratio is important to consider if a larger 
sample size is needed for a future study. 
The IPAQ was useful in assessing activity levels of the cohort. 
However, many participants found it difficult to quantify certain activ-
ities such as “time spent sitting” or they overestimated their times, as they 
Table 2 
Demographics of study cohort and groups of the trial. *1  Chef, 1  Car mechanic.   
Total (N  48) Group 1 (N  16) Group 2 (N  16) Group 3 (N  16) P 
Age Years Median (Min-Max) 60 (50–70) 59 (50–70) 61 (50–70) 62 (50–70) 0.85 
Gender (%) Male 8 (16.7) 1 (6.3) 2 (12.5) 5 (31.3) 0.14 
Female 40 (83.3) 15 (93.8) 14 (87.5) 11 (68.8) 
Religion (%) Islam 28 (58.3) 11 (68.8) 10 (62.5) 7 (43.8) 0.56 
Christian 17 (35.4) 4 (25.0) 6 (37.5) 7 (43.8) 
No data 3 (6.3) 1 (6.3) 0 (0.0) 2 (12.5) 
Tribe (%) Chagga 40 (83.3) 12 (75.0) 15 (93.8) 13 (81.3) 0.41 
Maasai 1 (2.1) 0 (0.0) 1 (6.3) 0 (0.0) 
Haya 2 (4.2) 1 (6.3) 0 (0.0) 1 (6.3) 
Nyaturu 1 (2.1) 1 (6.3) 0 (0.0) 0 (0.0) 
Pare 4 (8.3) 2 (12.5) 0 (0.0) 2 (12.5) 
Marital status (%) Married 27 (56.3) 8 (50.0) 10 (62.5) 9 (56.3) 0.12 
Widowed 13 (27.1) 6 (37.5) 2 (12.5) 5 (31.3) 
Divorced 5 (10.4) 1 (6.3) 4 (25.0) 0 (0.0) 
No data 3 (6.3) 1 (6.3) 0 (0.0) 2 (12.5) 
Village (%) Boma Ng’ombe 4 (8.3) 1 (6.3) 1 (6.3) 2 (12.5) 0.84 
Gezaulole 1 (2.1) 1 (6.3) 0 (0.0) 0 (0.0) 
Kengele 2 (4.2) 1 (6.3) 0 (0.0) 1 (6.3) 
Kengereka 1 (2.1) 0 (0.0) 1 (6.3) 0 (0.0) 
Kibaoni 2 (4.2) 1 (6.3) 0 (0.0) 1 (6.3) 
Kware 29 (60.4) 10 (62.5) 10 (62.5) 9 (56.3) 
Mkombozi 8 (16.7) 2 (12.5) 3 (18.8) 3 (18.8) 
Udoro 1 (2.1) 0 (0.0) 1 (6.3) 0 (0.0) 
Occupation (%) Farming/Animal Keeping 22 (45.8) 6 (37.5) 9 (56.3) 7 (43.8) 0.24 
Home-keeping 10 (20.8) 4 (25.0) 2 (12.5) 4 (25) 
Farming and Trading 6 (12.5) 2 (12.5) 1 (6.3) 3 (18.8) 
Trading 4 (8.3) 1 (6.3) 3 (18.8) 0 (0.0) 
Unemployed 2 (4.2) 1 (6.3) 1 (6.3) 0 (0.0) 
Skilled profession* 2 (4.2) 1 (6.3) 0 (0.0) 1 (6.3) 
Missing Data 2 (4.2) 1 (6.3) 0 (0.0) 1 (6.3) 
Alcohol (%) Never 19 (39.6) 6 (37.5) 6 (37.5) 7 (43.8) 0.83 
Ex-drinker 12 (25.0) 3 (18.8) 4 (25.0) 5 (31.3) 
Currently Drinking 17 (35.4) 7 (43.8) 6 (37.5) 4 (25.0) 
Smoking (%) Never 36 (75.0) 12 (75.0) 12 (75.0) 12 (75.0) 1.0 
Ex-smoker 12 (25.0) 4 (25.0) 4 (25.0) 4 (25.0)  
Table 3 
Hypertensive Grading of Cohort according to NICE31 (National Institute for 
Health and Care Excellence) & ESC32 (European Society of Cardiology) 
guidelines.   
Baseline Hypertensive Grading P 
Pre-hypertensive (%) Grade 1 (%) Grade 2 (%) 
Total (N  48) 8 (16.7) 20 (41.7) 20 (41.7)  
Group 1 (N  16) 1 (6.3) 6 (37.5) 9 (56.3) 0.14 
Group 2 (N  16) 5 (31.3) 6 (37.5) 5 (31.3) 
Group 3 (N  16) 2 (12.5) 8 (50) 6 (37.5)  
Table 4 
Baseline data of cohort. BMI  body mass index, ABPM  Ambulatory Blood Pressure Measurement, CBPM  Clinic Blood Pressure Measurement, MAP  Mean 
Arterial Pressure. *ABPM n  44 as 3 participants refused to perform the measurements.  
Variable (Baseline) Total (SD) n  47 Group 1 (SD) n  16 Group 2 (SD) n  16 Group 3 (SD) n  15 P 
Anthropometry Height (cm) 162.2 (8.3) 162.4 (7.4) 161.9 (7.9) 161.4 (9.3) 0.98 
Weight (kg) 72.3 (15.3) 76.6 (15.4) 69.0 (13.1) 71.4 (17.3) 0.36 
Upper Arm Circumference (cm) 31.2 (4.2) 32.6 (4.7) 30.3 (3.8) 30.7 (3.8) 0.24 
Waist Circumference (cm) 98.3 (11.0) 99.6 (10.0) 97.9 (11.5) 97.2 (12.2) 0.82 
BMI (kg/m2) 27.6 (5.4) 29.1 (5.8) 26.3 (4.7) 27.3 (5.7) 0.23 
Blood Pressure (mmHg) CBPM Systolic 151.0 (19.4) 155.8 (18.6) 150.0 (23.9) 147.0 (14.5) 0.45 
CBPM Diastolic 91.8 (11.7) 94.0 (10.5) 92.0 (15.0) 89.2 (9.0) 0.52 
CBPM Mean Arterial Pressure (MAP) 121.4 (14.1) 124.9 (13.0) 121.0 (18.7) 118.1 (8.6) 0.47 
*ABPM Systolic 140.4 (15.0) 141.9 (12.3) 131.6 (15.9) 137.0 (13.8) 0.55 
*ABPM Diastolic 88.4 (11.1) 90.2 (9.9) 81.2 (11.2) 82.7 (7.6) 0.08 
*ABPM MAP 112.3 (11.5) 113.9 (9.7) 104.3 (12.6) 107.6 (7.9) 0.27  
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explained they would farm and dig for 8 h without accounting for 
breaks. This may affect the quality of the data. Assessing activity levels 
was not a main aim for our study, but it is worth noting that many of 
these questions may need to be adapted should the IPAQ be utilised for a 
future study in this setting. 
In comparison to the ONT, the salivary strips provided quick and 
easily interpretable results which could be immediately explained to 
participants and did not require laboratory storage. However, as they 
are graded from a colour scale, salivary strips may be subject to inter-
pretive bias, and also cannot differentiate between participants of the 
same grade. To resolve this, a mobile application produced by the 
manufacturer can be used to interpret the strips and provide quantita-
tive data. This could be employed in a future trial to increase the 
sensitivity of this test. Ultimately, if analysis by ozone-based chem-
iluminescence of the saliva samples collected at the same time gave 
similar results to the saliva strips, it would be more feasible to use the 
salivary strips in future studies, especially in this setting, for both cost 
and convenience. 
4.1. Strength and limitations 
To our knowledge, a RCT of this nature has never been conducted in 
this population and is completely unique for a Sub-Saharan African 
setting. Utilising the Hai DSS meant that we had a known high preva-
lence of hypertension in the area from previous research, and a well- 
defined population. These factors indicate that this population would 
be an ideal target for any future larger scale trials and thus increases the 
importance of our findings. Most importantly, this study has yielded 
novel findings of the acceptability of using assessment tools such as 
ABPMs, blood samples, ONT test, IPAQs and salivary strips within a 
Tanzanian population that was unfamiliar with them. We have also 
demonstrated that our study protocol was feasible in a rural cohort, 
which may be of benefit for other dietary intervention studies. 
Certain factors may limit the generalizability of our results. Firstly, 
our study cohort was heavily gender biased towards women, and it is 
possible that men will have differing opinions on the acceptability of our 
study tools and intervention. Secondly, results may vary between vil-
lages that are within the same DSS. As our study participants were 
sampled from only two rural villages, the findings may not be wholly 
representative of other villages in the DSS, as well as other urbanized 
areas where the population would have differing lifestyle factors and 
dietary habits. Therefore, our results should be extrapolated to other 
SSA settings with careful consideration, as population lifestyles and diet 
may vary markedly. The timing of the interventions also coincided with 
Ramadan and over half of the participants were Muslim. It is important 
to recognize that effects of fasting may have had an influence on the BP 
measurements, although other studies investigating this influence have 
had mixed results [34]. 
4.2. Implications 
Overall, this pilot study indicates that a nutritional intervention of 
this nature is possible within a hypertensive African population. 
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Table 5 
MET (Metabolic Equivalents) scores of study cohort (N  44). Time spent when 
active is noted and multiplied by the energy demand of the corresponding ac-
tivity (Walking  3.3 METs, Moderate Activity  4 METs, Vigorous Activity  8 
METs). Activity Classification: High  >3000 METs per week, Moder-
ate  600–3000 METs per week, Low  <600 METs per week.   
METs Score of Study Cohort (per week) 
Walking Moderate 
Activity 
Vigorous 
Activity 
Total 
METs 
Lower Quartile 
(LQ) 
396 1680 0 5752 
Median 916 4920 0 10874 
Upper Quartile 
(UQ) 
2772 11760 6120 18925  
Fig. 2. Salivary strip30 grading determined by Berkeley colour scoring on NO test strips: Very Depleted (<20), Depleted (20–109), Low (110–219), Threshold 
(220–434), Target (435–869), High (>870). 
N. Kandhari et al.                                                                                                                                                                                                                              
Contemporary Clinical Trials Communications 16 (2019) 100472
8
Acknowledgements 
We would like to thank the participants for their valuable time 
dedicated to the study. 
Data Availability Statement 
The dataset used to generate the baseline data has been attached to 
the manuscript. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.conctc.2019.100472. 
References 
[1] R. Lozano, M. Naghavi, K. Foreman, et al., Global and regional mortality from 235 
causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the 
Global Burden of Disease Study 2010, The Lancet 380 (9859) (2012) 2095–2128, 
https://doi.org/10.1016/S0140-6736(12)61728-0. 
[2] Kahabi G. Isangula, John R. Meda, The burden of hypertension in the rural and 
urban populations of Tanzania: a review of trends, impacts and response, Tanzan. 
J. Health Sci. 1 (1) (2017). 
[3] M.J. Dewhurst, F. Dewhurst, W.K. Gray, et al., The high prevalence of hypertension 
in rural-dwelling Tanzanian older adults and the disparity between detection, 
treatment and control: a rule of sixths? J. Hum. Hypertens. 27 (2012) 374, https:// 
doi.org/10.1038/jhh.2012.59. 
[4] P.K. Whelton, R.M. Carey, W.S. Aronow, et al., ACC/AHA/AAPA/ABC/ACPM/ 
AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, 
evaluation, and management of high blood pressure in adults, in: A Report of the 
American College of Cardiology/American Heart Association Task Force on 
Clinical Practice Guidelines 2017, 2017, https://doi.org/10.1016/j. 
jacc.2017.11.006. 
[5] N.G. Hord, Y. Tang, N.S. Bryan, Food sources of nitrates and nitrites: the 
physiologic context for potential health benefits, Am. J. Clin. Nutr. 90 (1) (2009) 
1–10, https://doi.org/10.3945/ajcn.2008.27131. 
[6] A.W. Ashor, J. Lara, M. Siervo, Medium-term effects of dietary nitrate 
supplementation on systolic and diastolic blood pressure in adults: a systematic 
review and meta-analysis, J. Hypertens. 35 (7) (2017) 1353–1359, https://doi.org/ 
10.1097/hjh.0000000000001305. 
[7] J. Lara, A.W. Ashor, C. Oggioni, et al., Effects of inorganic nitrate and beetroot 
supplementation on endothelial function: a systematic review and meta-analysis, 
Eur. J. Nutr. 55 (2) (2016) 451–459, https://doi.org/10.1007/s00394-015-0872-7. 
[8] L.C. Gee, A. Ahluwalia, Dietary nitrate lowers blood pressure: epidemiological, pre- 
clinical experimental and clinical trial evidence, Curr. Hypertens. Rep. 18 (2016) 
17, https://doi.org/10.1007/s11906-015-0623-4. 
[9] A.J. Webb, N. Patel, S. Loukogeorgakis, et al., Acute blood pressure lowering, 
vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to 
nitrite, Hypertension 51 (3) (2008) 784–790, https://doi.org/10.1161/ 
hypertensionaha.107.103523. 
[10] S. Pietro, Nitrate in vegetables: toxicity, content, intake and EC regulation, J. Sci. 
Food Agric. 86 (1) (2006) 10–17, https://doi.org/10.1002/jsfa.2351. 
[11] M. Siervo, J. Lara, I. Ogbonmwan, et al., Inorganic nitrate and beetroot juice 
supplementation reduces blood pressure in adults: a systematic review and meta- 
analysis, J. Nutr. 143 (6) (2013) 818–826, https://doi.org/10.3945/ 
jn.112.170233. 
[12] V. Bond, B.H. Curry, R.G. Adams, et al., Effects of nitrate supplementation on 
cardiovascular and autonomic reactivity in African-American females, ISRN 
Physiol. 2014 (2014) 7, https://doi.org/10.1155/2014/676235. 
[13] W.-W. Wang, X.-S. Wang, Z.-R. Zhang, et al., A meta-analysis of folic acid in 
combination with anti-hypertension drugs in patients with hypertension and 
hyperhomocysteinemia, Front. Pharmacol. 8 (585) (2017), https://doi.org/ 
10.3389/fphar.2017.00585. 
[14] S.N. Doshi, I.F.W. McDowell, S.J. Moat, et al., Folic acid improves endothelial 
function in coronary artery disease via mechanisms largely independent of 
homocysteine lowering, Circulation 105 (1) (2002) 22–26, https://doi.org/ 
10.1161/hc0102.101388. 
[15] A.E. Stanhewicz, W.L. Kenney, Role of folic acid in nitric oxide bioavailability and 
vascular endothelial function, Nutr. Rev. 75 (1) (2017) 61–70, https://doi.org/ 
10.1093/nutrit/nuw053. 
[16] J. Kayima, R.K. Wanyenze, A. Katamba, et al., Hypertension awareness, treatment 
and control in Africa: a systematic review, BMC Cardiovasc. Disord. 13 (1) (2013) 
54, https://doi.org/10.1186/1471-2261-13-54. 
[17] N.R. Mosha, M. Mahande, A. Juma, et al., Prevalence, awareness and factors 
associated with hypertension in North West Tanzania, Glob. Health Action 10 (1) 
(2017), https://doi.org/10.1080/16549716.2017.1321279. 
[18] M. Mayige, G. Kagaruki, K. Ramaiya, et al., Non communicable diseases in 
Tanzania: a call for urgent action, Tanzan. J. Health Res. 13 (5) (2011). 
[19] J. Maginga, M. Guerrero, E. Koh, et al., Hypertension control and its correlates 
among adults attending a hypertension clinic in Tanzania, J. Clin. Hypertens. 18 
(3) (2016) 207–216, https://doi.org/10.1111/jch.12646. 
[20] A.L. Whitehead, S.A. Julious, C.L. Cooper, et al., Estimating the sample size for a 
pilot randomised trial to minimise the overall trial sample size for the external pilot 
and main trial for a continuous outcome variable, Stat. Methods Med. Res. 25 (3) 
(2016) 1057–1073, https://doi.org/10.1177/0962280215588241. 
[21] V. Kapil, R.S. Khambata, A. Robertson, et al., Dietary nitrate provides sustained 
blood pressure lowering in hypertensive patients: a randomized, phase 2, double- 
blind, placebo-controlled study, Hypertension 65 (2) (2015) 320–327, https://doi. 
org/10.1161/HYPERTENSIONAHA.114.04675. 
[22] WHO, The WHO STEPS Instrument: the WHO STEPwise Approach to Chronic 
Disease Risk Factor Surveillance (STEPS), World Health Organisation, Geneva, 
2008. 
[23] I.E.M. Mobil-O-Graph® PWA, Available from: https://www.iem. 
de/en/products/mobil-o-graph.html#pwa, 2018. 
[24] P.M. Franssen, B.P. Imholz, Evaluation of the Mobil-O-Graph new generation 
ABPM device using the ESH criteria, Blood Press. Monit. 15 (4) (2010) 229–231, 
https://doi.org/10.1097/MBP.0b013e328339be38. 
[25] C.R. Jones, K. Yalor, P. Chowienczyk, et al., A validation of the Mobil O Graph 
(version 12) ambulatory blood pressure monitor, Blood Press. Monit. 5 (4) (2000) 
233–238. 
[26] IPAQ, Guidelines for the Data Processing and Analysis of the "International 
Physical Activity Questionnaire, 2005. Protocol for Short Form. 
[27] M. Siervo, S.J. Jackson, L.J.C. Bluck, In-vivo nitric oxide synthesis is reduced in 
obese patients with metabolic syndrome: application of a novel stable isotopic 
method, J. Hypertens. 29 (8) (2011) 1515–1527, https://doi.org/10.1097/ 
HJH.0b013e3283487806. 
[28] S.J. Jackson, M. Siervo, E. Persson, et al., A novel derivative for the assessment of 
urinary and salivary nitrate using gas chromatography/mass spectrometry, Rapid 
Commun. Mass Spectrom. 22 (24) (2008) 4158–4164, https://doi.org/10.1002/ 
rcm.3841. 
[29] Berkeley Life, Nitric oxide saliva test strips, Available from: https://www. 
berkeleylife.com/nitric-oxide-saliva-test-strips/, 2018. 
[30] A.-W. Chan, J.M. Tetzlaff, D.G. Altman, et al., SPIRIT 2013 statement: defining 
standard protocol items for clinical trials, Ann. Intern. Med. 158 (3) (2013) 
200–207, https://doi.org/10.7326/0003-4819-158-3-201302050-00583. 
[31] National Bureau of Statistics, Basic Demographic and Socio-Economic Profile - 
Kilimanjaro Region. 2012 Population and Housing Census, The United Republic of 
Tanzania, 2016. 
[32] Bureau of Statistics Planning Commission, Macro International Inc, Tanzania 
Demographic and Health Survey 1996 Calverton, Bureau of Statistics and Macro 
International Inc., Maryland, 1997. 
[33] Climate-DataOrg, Climate: Kilimanjaro, Available from: https://en.climate-data. 
org/africa/tanzania/kilimanjaro-1714/. 
[34] J.F. Trepanowski, R.J. Bloomer, The impact of religious fasting on human health, 
Nutr. J. 9 (2010), https://doi.org/10.1186/1475-2891-9-57, 57-57. 
N. Kandhari et al.                                                                                                                                                                                                                              
